The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury

Three randomized control trials (Canagliflozin Cardiovascular Assessment Study, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME], and Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 [DECLARE-TIMI 58]) show...

Full description

Bibliographic Details
Main Authors: Chang Chu, Yong-Ping Lu, Lianghong Yin, Berthold Hocher
Format: Article
Language:English
Published: Karger Publishers 2019-04-01
Series:Kidney & Blood Pressure Research
Subjects:
Sodium-glucose co-transporter 2 inhibitors
Acute renal failure
Pharmacokinetics
Pharmacodynamics
Empagliflozin
Canagliflozin
Dapagliflozin
Online Access:https://www.karger.com/Article/FullText/498963

Internet

https://www.karger.com/Article/FullText/498963

Similar Items